Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.
暂无分享,去创建一个
Naidong Weng | Philip Timmerman | Ronald de Vries | Mike Huang | Nini Bode | Purvi Jejurkar | Jan de Jong | Juthamas Sukbuntherng | Luc Sips | Tom Verhaeghe | P. Timmerman | Naidong Weng | R. de Vries | J. Sukbuntherng | T. Verhaeghe | J. Jong | L. Sips | Mike-Qingtao Huang | N. Bode | Purvi Jejurkar | Nini Bode
[1] A. Rosenwald,et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.
[2] J. Pinilla-Ibarz,et al. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. , 2014, P & T : a peer-reviewed journal for formulary management.
[3] Naidong Weng,et al. Mini FocuS iSSue : tieRed appRoach to BioanalySiS , 2014 .
[4] Magnus Knutsson,et al. Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum. , 2009, Bioanalysis.
[5] R. Pugh,et al. Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.
[6] M. Rangasamy,et al. Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. , 2015, Journal of pharmaceutical and biomedical analysis.
[7] Y. Alnouti,et al. The profile of bile acids and their sulfate metabolites in human urine and serum. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] J. Castillo,et al. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies , 2012, Expert opinion on investigational drugs.
[9] Vinod P. Shah,et al. Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007 .
[10] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[11] M. T. Donato,et al. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method[S] , 2012, Journal of Lipid Research.
[12] L. Leclercq,et al. Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men , 2015, Drug Metabolism and Disposition.
[13] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[14] Vinod P. Shah,et al. Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays , 2007 .
[15] Y. Alnouti. Bile Acid sulfation: a pathway of bile acid elimination and detoxification. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[16] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[17] M. Fouad,et al. Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection , 2015, Journal of analytical methods in chemistry.
[18] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[19] R. J. Briggs,et al. Method Transfer, Partial Validation, and Cross Validation: Recommendations for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team , 2014, The AAPS Journal.
[20] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Jennifer R. Brown. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies , 2014, Leukemia and Lymphoma.
[22] G. Neale,et al. Serum bile acids in liver disease , 1971, Gut.